Global Upper GI Series Market - Overview
An upper gastrointestinal (GI) series is also known as contrast radiography or upper gastrointestinal study, which is performed to detect abnormalities and diseases of GI tract. In this procedure, a contrast media is ingested or imparted into the digestive tract and X-rays are used to create radiographs of the desired portion. According to the National Institute of Diabetes and Digestive and Kidney Diseases, in 2010 approximately 60 to 70 million people were affected by major or minor GI diseases. This number is continuously increasing due to poor diet and increasing aging population. The global GI series market is driven mainly by increasing prevalence of GI diseases & gastric cancer, and changing lifestyle. Developments in the technologies, cost-effective methods, increasing aging population and government support for research have also affected the growth of the market positively. Whereas, availability of alternative therapies and limited applications of the method have hampered the growth of the market.
Further, the global upper GI series market is expected to grow at steady pace. Increasing prevalence of GI diseases, rising geriatric population and increasing healthcare expenditure are the major driving factors in the market. Apart from this, government support and developments in technology have also contributed to the growth of the market. However, availability of alternative treatments may hamper the growth of the market during the forecast period.
The global upper GI series market is segmented on the basis of test type, into standard barium upper GI series and double-contrast upper GI series. On the basis of imaging material, the market is segmented into: barium swallow, barium meal, and barium follow-through. On the basis of application, the market is segmented into: esophageal reflux, esophageal varices, ulcers, hiatal hernias, and others. On the basis of end users, it is segmented into: hospitals, clinics & laboratories, and other
Global Upper GI Series Market -
The global GI series market is segmented into four major regions: America, Europe, Asia Pacific and the Middle East & Africa. America accounts for the largest market for GI series. According to the National Institute of Diabetes and Digestive and Kidney Diseases, by 2010 more than 34 million Americans suffered from GI tract diseases and from which 20 million had suffered from chronic diseases. It was estimated that 8% of the U.S. population has chronic digestive diseases and 6% has acute digestive diseases. According to Federal Interagency Forum, 46 million people aged more than 65 years lived in the US in 2014, accounting for 15 percent of the total population. This increasing prevalence of GI diseases and increasing aging population in America has driven the growth of the market. American GI series market is segmented into North America and South America. North America contributes 80% of total market share owing to the well-developed healthcare sector, high healthcare expenditure and the government support for research. Europe accounts for the second largest market, which is followed by Asia Pacific. Asia Pacific is the fastest growing market in the globe.
Global Upper GI Series Market - Competitive Analysis
The prominent key players present in the global upper GI series test market are GastroIntestinal Endoscopy, GastroIntestinal Specialists, Eisai US, Cadila Pharmaceuticals Limited, PeaceHealth, Purdue Pharma L.P., Alfa Wassermann, NOVADAQ, Mount Sinai Beth Israel, AstraZeneca, Ironwood Pharmaceuticals and among others.
Global upper GI series market is a competitive market due to constant pressure to launch new products and cost-effective methods; many companies are investing in research and development of the products.
Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan and has launched number of product used as contrast media. The company has announced its partnership with AJINOMOTO CO.,INC. for the establishment of gastrointestinal specialty EA Pharma Co., Ltd.
GE Healthcare one of the leading American multinational company headquartered in US. It is the manufacturer and distributor of diagnostic imaging agents. OMNISCAN and VISIPAQUE are the major products of the company. Recently company has launch Clariscan which is a macrocyclic agent for the effective visualisation of abnormalities in the brain, spine and associated tissues.
Browse Full Report @ https://www.marketresearchfuture.com/reports/upper-gi-series-market-826